This protocol is judged by an institutional evaluate board, an unbiased team that reviews any clinical trials involving human beings. If a review requires a Program I drug, after the board approves the protocol as ethical, the scientists need to apply for an investigational new drug (IND) selection from the FDA.“It’s essential to do not forget